JMDC (4483) Q3 2025 earnings summary

Executive summary

• Consolidated revenue for FY2024 Q3 reached JPY 30,605 million, up 37% year-over-year, with operating profit up 2.6% to JPY 5,814 million and EBITDA up 27% to JPY 7,832 million.

• Profit attributable to owners was JPY 3,862 million, down 2.9% year-over-year, while comprehensive income increased 15.3% to JPY 4,603 million.

• Core Healthcare - Big Data business drove growth, with segment revenue up 50% year-over-year.

• Tele-medicine and Pep Up businesses also showed strong growth, with Pep Up sales up 44% and IDs reaching 6.98 million.

• Cancerscan acquisition impacted Q3 profit margins, but full-year performance is on track.

Financial highlights

• Revenue: JPY 30,605 million (+37% YoY), EBITDA: JPY 7,832 million (+27% YoY), margin at 26%.

• Operating profit: JPY 5,814 million (+3% YoY), profit attributable to owners: JPY 3,862 million (-3% YoY).

• Gross margin for the nine months was 57.7%, with EBITDA margin at 25.6%.

• Cash and cash equivalents at period-end were JPY 23,877 million, up JPY 9,403 million from March 31, 2024.

• Cancerscan contributed JPY 830 million revenue and -JPY 100 million EBITDA in Q3.

Outlook and guidance

• Management expects to achieve full-year revenue guidance, with profit targets more challenging due to increased fixed costs from proactive hiring.

• Full-year revenue forecast is JPY 43,000 million (+33% YoY), operating profit JPY 9,300 million (+33%), EBITDA JPY 12,000 million (+27%).

• Profit attributable to owners is projected at JPY 6,200 million (+35%), with basic EPS of JPY 94.90.

• No changes to previously announced earnings or dividend forecasts.

• Upfront investments in new data and business areas are expected to drive growth and profitability in the next fiscal year.